Logo image of TECX

TECTONIC THERAPEUTIC INC (TECX) Stock News

NASDAQ:TECX - Nasdaq - US8789721086 - Common Stock - Currency: USD

22.44  -1.06 (-4.51%)

After market: 22.44 0 (0%)

TECX Latest News, Press Relases and Analysis

News Image
a month ago - Tectonic Therapeutic

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary...

News Image
a month ago - Zacks Investment Research

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News Image
a month ago - Tectonic Therapeutic

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in...

News Image
8 months ago - Tectonic Therapeutic

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

American Heart Association (AHA) poster to be presented on November 16, 2024...

News Image
2 months ago - Tectonic Therapeutic

Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort

News Image
3 months ago - Tectonic Therapeutic

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent business highlights.

News Image
4 months ago - Tectonic Therapeutic

Tectonic Announces $185 Million Private Placement

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million.

News Image
4 months ago - Tectonic Therapeutic

Tectonic Announces $185 Million Private Placement

News Image
4 months ago - Tectonic Therapeutic

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved...

News Image
6 months ago - Tectonic Therapeutic

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused...

News Image
7 months ago - Tectonic Therapeutic

Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused...

News Image
7 months ago - Tectonic Therapeutic

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable...

News Image
7 months ago - Tectonic Therapeutic

Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025First...

News Image
8 months ago - Tectonic Therapeutic

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

American Heart Association (AHA) poster to be presented on November 16, 2024